SK Plasma Launches Project to Localize Essential Medicines in Turkey
Production Facility with Annual Capacity of 600,000 Liters via Local Joint Venture
Local Production of Essential Medicines Including Albumin and Immunoglobulin
Technology Transfer and Contract Manufacturing in Parallel... Laying the Groundwo
SK Plasma has officially launched its project to localize plasma fractionation products in Turkey. This business model goes beyond simply exporting finished products, combining the establishment of local production facilities, technology transfer, quality control, and workforce training. The aim is to expand the supply chain of essential pharmaceuticals for K-Bio.
On June 15, SK Plasma announced that it had held a groundbreaking ceremony for a plasma fractionation plant at the Cubuk site in Ankara, Turkey. The project is based on the “shareholders' agreement” signed in November of last year between SK Plasma and the Turkish Red Crescent for the construction of a plasma fractionation plant and the establishment of a joint venture. Through the joint venture Proturk, established by both parties, a production facility with a total floor area of approximately 36,000 square meters and an annual plasma processing capacity of 600,000 liters will be constructed.
On the 11th (local time), at the groundbreaking ceremony for SK Plasma's Turkey plasma fractionation manufacturing plant held at the Presidential Palace of Turkey, Jaehyun Ahn, President of SK Chemicals (left), greets Recep Tayyip Erdogan, President of Turkey (right). SK Plasma
View original imageThis facility will produce albumin (ABM), intravenous immunoglobulin (IVIG), and factor VIII (FVIII), with the goal of completing construction in the second half of 2028 and commencing commercial production in 2030.
Plasma fractionation products are designated as essential medicines by the World Health Organization (WHO) and are used to treat severe diseases, making them difficult to substitute. Countries lacking production infrastructure have a high dependence on imports, leaving them vulnerable to supply disruptions during periods of supply chain instability.
As a major shareholder and technology partner in Proturk, SK Plasma will transfer core plasma fractionation technology and support the construction of production facilities, quality management, local workforce training, and preparations for commercial production. The company will receive technology fees and, based on its 15% equity stake, participate in the management of the joint venture. In addition, SK Plasma plans to operate a contract manufacturing (CMO) project, supplying finished products using plasma sourced in Turkey that will be fractionated at its Andong plant until commercial production begins in Turkey.
SK Plasma’s plasma fractionation localization solution business model integrates technology transfer, establishment of production facilities, operational support, and equity participation, moving beyond simple finished product exports. This allows local countries to secure a production base for essential medicines and medical sovereignty, while SK Plasma can establish a long-term business foundation based on technology fees and equity ownership.
Based on this localization solution business model, SK Plasma is working to build a “federation” supply system that organically connects global production bases, starting with Andong in Korea, Indonesia, and Turkey.
The company explains that as global production bases expand, this will help reduce blind spots in countries lacking infrastructure and exposed to supply disruptions for essential medicines, and contribute to securing medical sovereignty. Furthermore, if production disruptions or surges in demand occur in a specific country, mutual support among production bases will enhance both supply stability and business scalability.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seungjoo Kim, CEO of SK Plasma, stated, “By establishing stable supply systems based on production bases in Indonesia and Turkey, we will expand the business scope of K-Bio into the European and Middle Eastern markets.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.